Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3265/Nefrologia.pre2013.Jul.12040 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dabigatran-induced esophagitis with full circumferential blue pigmentation.
DEN Open
April 2024
Department of Gastroenterology and Hepatology Graduate School of Biomedical Sciences, Nagasaki University Nagasaki Japan.
Dabigatran is a useful and widely used drug for stroke prevention in patients with atrial fibrillation. However, it has been reported to cause esophagitis. Herein, we report the case of a 77-year-old man with dabigatran-induced esophagitis with blue pigmentation, which is known to be a rare adverse effect.
View Article and Find Full Text PDFIdarucizumab reverses dabigatran-induced anticoagulation in treatment of gastric bleeding: A case report.
World J Clin Cases
March 2022
Department of Gastroenterology, Hospital of Integrated Traditional Chinese and Western Medicine, Beijing 100039, China.
Background: The drug instructions for dabigatran recommend adjusting the dosage to 110 mg twice daily for patients with bleeding risk, and performing at least one renal function test per year for patients with moderate renal impairment. However, owing to chronic insidiously worsening renal insufficiency, dabigatran can still accumulate abnormally, necessitating therapy with idarucizumab to reverse the anticoagulation due to severe erosive gastritis with widespread stomach mucosal bleeding.
Case Summary: A 76-year-old woman with a history of atrial fibrillation who took dabigatran 110 mg twice daily as directed to lessen the chance of stroke, was transported to the hospital with hematemesis and melena.
Idarucizumab (PRAXBIND®) as a sole reversal agent in an unstable hemorrhagic shock patient on an unknown anticoagulant with elevated protime/international normalized ratio (PT/INR).
Am J Emerg Med
August 2021
Sarasota Memorial Hospital, Sarasota, FL, United States. Electronic address:
Dabigatran is a direct oral anticoagulant thrombin inhibitor approved for stroke prophylaxis in patients with non-valvular atrial fibrillation and prophylaxis or treatment of venous thromboembolism. Since approval, there has been increasing concern regarding bleeding risk, predominantly in the elderly population and those with renal disease. We present a case of an 85-year-old female with an unknown medication history, shortness of breath and severe anemia due to an upper gastrointestinal bleed.
View Article and Find Full Text PDFThe Risks of Exfoliative Esophagitis in Patients with Atrial Fibrillation: A retrospective observational study.
Medicine (Baltimore)
August 2020
Department of Gastroenterology.
The aging of the population has resulted in atrial fibrillation (AF) becoming increasingly prevalent. Treatment focuses on the prevention of thromboembolism through the use of catheter ablation or drug therapy with anticoagulants, such as warfarin or direct oral anticoagulants (DOACs). Dabigatran-induced exfoliative esophagitis has been reported as a rare side effect of DOACs.
View Article and Find Full Text PDFDabigatran-induced esophagitis: A case report.
Medicine (Baltimore)
April 2020
Department of Gastroenterology, Shanghai Hospital of Integrated Traditional Chinese and Western Medicine.
Rationale: Dabigatran is an anticoagulant medication that has been widely used to prevent strokes caused by atrial fibrillation, deep vein thrombosis, and pulmonary embolism. However, the potential adverse effect of dabigatran of gastrointestinal mucosal injury is often neglected, and even induces esophagitis.
Patient Concerns: A 77-year-old woman was admitted to the hospital with symptoms of progressive retrosternal pain, upper abdominal discomfort, and dysphagia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!